62 related articles for article (PubMed ID: 32346078)
1. Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin's lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study.
Di Renzo N; Musso M; Scimè R; Cupri A; Perrone T; De Risi C; Pastore D; Guarini A; Mengarelli A; Benedetti F; Mazza P; Capria V; Chiusolo P; Cupelli L; Federico V; Bozzoli V; Messa AR; Codega P; Bonizzoni E; Specchia G
Bone Marrow Transplant; 2020 Nov; 55(11):2114-2120. PubMed ID: 32346078
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of netupitant/palonosetron in preventing nausea and vomiting in diffuse large B cell lymphoma patients undergoing R-CHOP chemotherapy.
Kwak K; Park Y; Kim BS; Kang KW
Sci Rep; 2024 May; 14(1):11229. PubMed ID: 38755279
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of netupitant/palonosetron for prevention of chemotherapy-induced nausea/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation.
Bubalo JS; Radke JL; Bensch KG; Chen AI; Misra S; Maziarz RT
J Oncol Pharm Pract; 2024 Mar; 30(2):304-312. PubMed ID: 37151021
[No Abstract] [Full Text] [Related]
4. Retrospective Evaluation of a Dexamethasone Sparing Antiemetic Regimen: An Antiemetic Prophylaxis Study on NEPA (Netupitant Plus Palonosetron) for Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in Cancer Patients.
Agre S; Agre M; Pol P; Tonse M; Mohanty M; Shaikh A
Cureus; 2023 Nov; 15(11):e49763. PubMed ID: 38161895
[TBL] [Abstract][Full Text] [Related]
5. Comparison of netupitant/palonosetron with 5-hydroxytryptamine-3 receptor antagonist in preventing of chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.
Zhang H; Zeng Q; Dong T; Chen X; Kuang P; Li J; Wu Q; Liu T; Niu T; Liu Z; Ji J
Front Oncol; 2023; 13():1280336. PubMed ID: 38074658
[TBL] [Abstract][Full Text] [Related]
6. Fixed-Dose Netupitant and Palonosetron for Chronic Nausea in Cancer Patients: A Double-Blind, Placebo Run-in Pilot Randomized Clinical Trial.
Hui D; Puac V; Shelal Z; Liu D; Maddi R; Kaseb A; Javle M; Overman M; Yennurajalingam S; Gallagher C; Bruera E
J Pain Symptom Manage; 2021 Aug; 62(2):223-232.e1. PubMed ID: 33388382
[TBL] [Abstract][Full Text] [Related]
7. An Open-Label, Single-Arm, Multicenter, Observational Study Evaluating the Safety and Effectiveness of Akynzeo® in the Management of Chemotherapy-Induced Nausea and Vomiting in India.
Gupta S; Mv C; Thomas B; Biswas G; Gupta S; Dattatreya PS; Bhagat S; Patil S; Bhushan S; Barkate H
Cureus; 2024 Mar; 16(3):e56447. PubMed ID: 38638750
[TBL] [Abstract][Full Text] [Related]
8. Netupitant PET imaging and ADME studies in humans.
Spinelli T; Calcagnile S; Giuliano C; Rossi G; Lanzarotti C; Mair S; Stevens L; Nisbet I
J Clin Pharmacol; 2014 Jan; 54(1):97-108. PubMed ID: 24122871
[TBL] [Abstract][Full Text] [Related]
9. The effect of breathing exercises on chemotherapy-induced nausea and vomiting in autologous hematopoietic stem cell transplantation patients: A randomized controlled trial.
Genç Z; Can G; Koç Uyan E; Üre ÜB
Eur J Oncol Nurs; 2024 May; 70():102618. PubMed ID: 38820708
[TBL] [Abstract][Full Text] [Related]
10. Correction: An Open-Label, Single-Arm, Multicenter, Observational Study Evaluating the Safety and Effectiveness of Akynzeo® in the Management of Chemotherapy-Induced Nausea and Vomiting in India.
Mv C; Thomas B; Biswas G; Gupta S; Dattatreya PS; Bhagat S; Patil S; Bhushan S; Barkate H
Cureus; 2024 Apr; 16(4):c169. PubMed ID: 38651087
[TBL] [Abstract][Full Text] [Related]
11. Management of Chemotherapy-Induced Nausea and Vomiting (CINV): A Short Review on the Role of Netupitant-Palonosetron (NEPA).
Lorusso V; Russo A; Giotta F; Codega P
Core Evid; 2020; 15():21-29. PubMed ID: 32802009
[TBL] [Abstract][Full Text] [Related]
12. Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation.
Apolito V; Giaccone L; Ferrero S; Larocca A; Cavallo F; Coscia M; Beggiato E; Butera S; Martella F; Dainese C; Cetani G; Scaldaferri M; Cattel F; Boccadoro M; Ferrero D; Bruno B; Cerrano M
Ann Hematol; 2020 Sep; 99(9):2197-2199. PubMed ID: 32661577
[No Abstract] [Full Text] [Related]
13. Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study.
Chang J; Chen G; Wang D; Wang G; Lu S; Feng J; Li W; Li P; Lanzarotti C; Chessari S; Zhang L
Cancer Med; 2020 Jul; 9(14):5134-5142. PubMed ID: 32472742
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of netupitant/palonosetron and dexamethasone in classical Hodgkin's lymphoma patients with inadequate chemotherapy-induced nausea and vomiting prophylaxis with palonosetron and dexamethasone: a single-center real-life experience.
Zilioli VR; Muzi C; Minga P; Codega P; Crucitti L; Meli E; Esposito A; Panico C; Rusconi C; Cairoli R
Int J Hematol Oncol; 2020 Feb; 9(1):IJH23. PubMed ID: 32382409
[TBL] [Abstract][Full Text] [Related]
15. NEPA as antiemetic prophylaxis after failure of 5HT
Valerio MR; Gebbia V; Borsellino N; Vecchia M; Serretta V; Pardo S; Cipolla C; Galanti D
J Oncol Pharm Pract; 2021 Apr; 27(3):609-613. PubMed ID: 32507099
[TBL] [Abstract][Full Text] [Related]
16. Capsule-related dysphagia and the use of netupitant/palonosetron (Akynzeo™) capsules - A report of two cases and a solution.
Behbahany K; Bubalo J
J Oncol Pharm Pract; 2021 Jul; 27(5):1284-1286. PubMed ID: 33100182
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of intravenous NEPA, a fixed NK
Aapro M; Navari RM; Roeland E; Zhang L; Schwartzberg L
Crit Rev Oncol Hematol; 2021 Jan; 157():103143. PubMed ID: 33260048
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of a novel, fixed dose combination of netupitant and palonosetron in prevention of chemotherapy induced nausea and vomiting: A real-life study from India.
Vaswani B; Bhagat S; Patil S; Barkate H
World J Clin Oncol; 2020 Aug; 11(8):606-613. PubMed ID: 32879847
[TBL] [Abstract][Full Text] [Related]
19. Antiemetics: ASCO Guideline Update.
Hesketh PJ; Kris MG; Basch E; Bohlke K; Barbour SY; Clark-Snow RA; Danso MA; Dennis K; Dupuis LL; Dusetzina SB; Eng C; Feyer PC; Jordan K; Noonan K; Sparacio D; Lyman GH
J Clin Oncol; 2020 Aug; 38(24):2782-2797. PubMed ID: 32658626
[TBL] [Abstract][Full Text] [Related]
20. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type.
Weinstein C; Jordan K; Green S; Khanani S; Beckford-Brathwaite E; Vallejos W; Pong A; Noga SJ; Rapoport BL
BMC Cancer; 2020 Sep; 20(1):918. PubMed ID: 32988373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
